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Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of
complement with diverse functions spanning from host defense to embryonic
development. CL-11 is found in the circulation in heterocomplexes with the homologous
collectin-10 (CL-10). Abnormal CL-11 plasma levels are associated with the presence
of disseminated intravascular coagulation, urinary schistosomiasis, and congenital
disorders. Although there has been a marked development in the characterization of
CL-11 there is still a scarcity of clinical tools for its analysis. Thus, we generated
monoclonal antibodies and developed a quantitative ELISA to measure CL-11 in the
circulation. The antibodies were screened against recombinant CL-11 and validated
by ELISA and immunoprecipitation of serum and plasma. The best candidates were
pairwise compared to develop a quantitative ELISA. The assay was validated regarding
its sensitivity, reproducibility, and dilution linearity, demonstrating a satisfactory variability
over a working range of 0.29–18.75 ng/ml. The mean plasma concentration of CL-11
in healthy controls was determined to be 289.4 ng/ml (range 143.2–459.4 ng/ml), highly
correlated to the levels of CL/10/11 complexes (r = 0.729). Plasma CL-11 and CL-10/11
co-migrated in size exclusion chromatography as two major complexes of ∼400 and
>600 kDa. Furthermore, we observed a significant decrease at admission in CL-11
plasma levels in patients admitted to intensive care with systemic inflammatory response
syndrome. By using the in-house antibodies and recombinant CL-11, we found that
CL-11 can bind to zymosan independently of calcium by a separate site from the
carbohydrate-binding region. Finally, we showed that CL-11/MASP-2 complexes trigger
C4b deposition on zymosan. In conclusion, we have developed a specific and sensitive
ELISA to investigate the ever-expanding roles of CL-11 in health and disease and shown
a novel interaction between CL-11 and zymosan.
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INTRODUCTION
CL-11 (alias collectin-11 and CL-K1) is a pattern recognition molecule (PRM) of the lectin
pathway of complement with diverse functions such as pathogen recognition, tissue homeostasis,
and embryonic development (1–4). It is the most recently discovered member of the collectin
family, mammalian C-type lectins involved in the innate immune response of the host.
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Collectins recognize conserved pathogen-specific structures
and altered-self molecules and mediate their removal by,
among others, agglutination, complement activation, and
modulation of inflammatory and adaptive immune responses
(5). Collectins share a common bouquet-like structure, with
monomeric subunits that assemble into oligomers of trimers.
Each monomeric subunit is, in turn, composed of a cysteine-
rich N-terminal region, a collagen-like domain, an α-helical neck
domain, and a C-terminal carbohydrate recognition domain
(CRD). The biological functions of the collectins rely on the high-
avidity binding resulting from the oligomerization and clustering
of the CRDs.
CL-11 is a secreted collectin found in the circulation (6–8).
Elevated CL-11 plasma levels are associated with a decreased
risk of contracting urinary schistosomiasis (9) and the presence
of disseminated intravascular coagulation (8), characterized by
simultaneous clotting and bleeding that frequently leads to
multiple organ failure and death. CL-11 deficiency is one of
the causes of the 3MC (Malpuech, Michels, Mingarelli, and
Carnevale) syndrome (3, 10), a congenital disorder associated
with craniofacial dysmorphism, mental retardation, growth
deficiency, and physical abnormalities. CL-11 is expressed
ubiquitously in the body and it appears to play an important role
in maintaining homeostasis in the tissue of expression (1, 11).
During embryonic development, CL-11 is highly expressed in the
craniofacial cartilage and vertebral bodies, where together with
MASP-3 and CL-10, may act as a guidance cue for neural crest
cell migration (12). In the mature kidney, locally-produced CL-
11 appears to be critical for the development of renal injury after
hypoxic and hypothermic stress (13), while in the retina local CL-
11 facilitates phagocytosis of photoreceptor outer segments and
modulates cytokine production in the retina (4).
Recently, CL-11 has been observed to circulate in complex
with another member of the collectin family, CL-10 (collectin-
10, CL-L1), forming highmolecular weight heterocomplexes (i.e.,
CL-10/11) that interact strongly with the MASPs (14). Upon
binding of CL-11 or CL-10/11 heterocomplexes to carbohydrate
structures on the surface of microorganisms, the MASPs activate
complement by cleaving C4 and C2 and generating the lectin
pathway C3 convertase (C4b2a) (2, 15). Besides their role
as the central lectin pathway enzymes, the MASPs are also
involved in a variety of biological processes (16–18). MASP-1
has a particularly broad substrate-specificity and it is known to
participate in the coagulation cascade, inflammatory reactions,
and cell activation; MASP-2 is associated with the development
of renal ischemia/reperfusion injury; while MASP-3 might be
involved in the modulation of the alternative pathway by
activating pro-FD in resting blood.
The multiplicity of biological functions attributed to CL-11
results from its ability to both associate with the MASPs and to
interact with a broad range of self and non-self structures, such
as yeast, bacteria, viruses, and apoptotic cells (1, 6, 19). Glycan
array studies revealed that CL-11 has a preference toward high-
mannose oligosaccharides and a subset of fucosylated glycans
(10). This unusual binding specificity, different from the other
collectins, can be explained by the presence of an extended
binding site on the CRD that recognizes both the terminal and
the penultimate sugar. Moreover, CL-11 has been observed to
bind to certain ligands—e.g., nucleic acids (19), Aspergillus (2),
and 9-O-acetylneuraminic acid (10)—in the absence of calcium
via a binding site distinct from the carbohydrate-binding region.
Though the biological importance of CL-11 is evident, there
is still a scarcity of clinical tools for its analysis. In this study,
we generated monoclonal antibodies (mAbs) for the study of
human CL-11. The mAbs were screened against serum and
plasma using different immunological methods. Furthermore, we
developed a quantitative ELISA based on two mAbs to measure
the concentration of CL-11 in the circulation. The assay was
thoroughly validated and used to determine the levels of CL-11 in
plasma from healthy individuals. Ourmeasurements of CL-11 are
in good agreement with the literature and are tightly associated
with those of CL-10/11. By size exclusion chromatography of
plasma, we show that CL-11 forms complexes of 300–400 kDa
and>600 kDa with a distinct composition of CL-10 glycosylation
states and CL-11 isoforms. Finally, we demonstrate that CL-
11 recognizes zymosan in a calcium-independent manner, and
triggers C4b deposition in the presence of MASP-2.
MATERIALS AND METHODS
Buffers
The following buffers were used: PBS (10.1mM disodium
phosphate, 1.5mM monopotassium phosphate, 137mM NaCl,
2.7mM KCl), PBS-Tw (PBS, 0.5% Tween-20), TBS-Tw ±
Ca/EDTA/Mg-EGTA (10mMTris, 150mMNaCl, 0.05% Tween-
20,±2.5mMCaCl2/10mM EDTA/2mMMgCl2, 10mM EGTA),
sample buffer (TBS-Tw-EDTA, 0.1% v/v bovine serum), barbital-
Tw ± EDTA (4mM sodium barbitone, 145mM NaCl, 2.6mM
CaCl2, 2.1mMMgCl2, with 0.05% Tween-20,± 5mM EDTA).
Generation of Anti-CL-11 Monoclonal
Antibodies (mAbs)
Two outbred NMRI mice were immunized subcutaneously
three times with 25 µg of purified recombinant CL-11 (rCL-
11) (R&D, USA) adsorbed to Al(OH)3 and diluted 1:1 with
Freund’s incomplete adjuvant (Sigma-Aldrich, USA). Three days
prior to the fusion, the mice received a final intravenous
injection of 25 µg of antigen and adrenalin. The fusion and
subsequent selection were done according to the principles of
the hybridoma technology (20). Positive clones were screened
in MaxiSorp microtiter plates (Thermo Fisher Scientific, USA)
coated with 0.6µg/ml of polyclonal antibody (pAb) rabbit
anti-CL-11 (15269-1-AP, Proteintech, USA) and in-house rCL-
11 as antigen. Selected mAbs were purified using a HiTrap
Protein G column in an Äkta Pure system (both from GE
Healthcare, UK). Briefly, clarified hybridoma supernatant was
applied onto the column and washed until a stable UV reading
was observed. Bound antibodies were eluted with 0.5% citric acid
and neutralized with 0.1M Tris pH 9. Elution fractions were
pooled and dialyzed against PBS. MAbs were biotinylated with
20% w/w (+)-Biotin N-hydroxysuccinimide ester (Sigma, USA)
for 3 h at room temperature (RT), followed by dialysis against
PBS to remove unreacted biotin.
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Production of Recombinant Proteins
Recombinant CL-11 (rCL-11) and CL-10 (rCL-10) were
produced in Flp-InTM-CHO cells (Invitrogen, USA). The coding
sequences (NM_024027.4 and NM_006438.4, respectively)
were retrieved from the RefSeq NCBI nucleotide database
and cloned into pcDNATM5/FRT vectors flanked by two
Flp recombinase target (FRT) sites. Stable transfectants were
generated by co-transfecting the coding vectors with a pOG44
plasmid encoding the Flp recombinase. Positive clones were
selected for Hygromycin resistance and grown in Ham’s F-12
Nutrient Mix supplemented with 0.5% FBS, 0.1 mg/ml of
Penicillin/Streptomycin (Sigma) and 2mM of L-Glutamine
(all from Gibco, Thermo Fisher Scientific unless otherwise
stated) according to the manufacturer’s recommendations. The
concentration of rCL-11 in the supernatant was calculated using
commercially-available rCL-11 (R&D) as calibrator.
Immunoprecipitation
Anti-CL-11 mAbs Hyb-15 and Hyb-17 (described in section
Generation of Anti-CL-11 Monoclonal Antibodies and
Development of a CL-11 Specific Sandwich ELISA), or mouse
IgG1κ isotype control (BD Biosciences, USA) (2 µg each)
were coupled to 25 µl of sheep anti-mouse IgG Dynabeads
(Invitrogen) end-over-end for 30min at RT. The conjugated
beads were washed with PBS-Tw and incubated end-over-end 1 h
at RT with serum diluted 1:1 in TBS-Tw-EDTA. After washing
with PBS-Tw, bound CL-11 was eluted with 0.5% citric acid and
subjected to SDS-PAGE as described below.
SDS-Page and Western Blot
Denatured samples were separated by electrophoresis in
NuPAGE R© Tris-Acetate 3–8% gels (Invitrogen, USA)
according to the manufacturer’s recommendation. Proteins
were blotted onto a PVDF membrane (Amersham Bioscience,
UK). Membranes were blocked with 5% skim milk (Merck
Millipore, USA) and incubated overnight with 0.2µg/ml of
pAb rabbit anti-CL-11 (15269-1-AP, Proteintech) followed by
1 h incubation with pAb swine anti-rabbit-HRP (P0399, Dako,
Denmark) in a 1:5000 dilution. After thorough washing, the
membranes were developed with SuperSignalTM West Femto
Maximum Sensitivity Substrate (Thermo Fisher Scientific) and
imaged with Microchemi (Bio-imaging systems, Israel).
CL-11 Specific Sandwich ELISA
MaxiSorp microtiter plates were coated overnight at 4◦C with
2µg/ml mAb Hyb-17 in PBS. Serial dilutions of the calibrator,
serum and plasma samples in sample buffer were applied to
the plate and incubated for 2 h, followed a 2 h incubation with
2µg/ml of biotinylated mAb Hyb-15 in PBS-Tw. Streptavidin-
HRP conjugate (RPN1231V, Sigma) was added to the wells for
1 h in a 1:2000 dilution in PBS-Tw. TMB One (KemEnTec
Diagnostics, Denmark) was used as substrate. The reaction was
stopped with 0.2M H2SO4 and the optical density (OD) was
recorded at 450 nm using an ELx80 absorbance reader (BioTek,
USA). Plates were washed with PBS-Tw between steps and unless
otherwise stated all incubations took place at RT. The optimal
combination and concentration of mAbs was determined using
a two-dimensional of capture and detection antibodies against
serial dilutions of serum and plasma and rated according to their
signal intensity and signal-to-noise ratio. The optimal incubation
times and sample buffer composition were determined based on
the same criteria.
Assay Validation: Parallelism, Precision, Limit of
Detection, Working Range, and Variation
Supernatant from Flp-In CHO cells expressing rCL-11 was used
as calibrator. The calibrator was applied in a two-fold dilution
to generate an eight-point curve with a concentration ranging
from 37.5 to 0.29 ng/ml. OD values from serial dilutions of
the calibrator, commercial rCL-11 (R&D), serum and EDTA
plasma pools (25 and 10 donors, respectively) were logistically-
transformed and a log(agonist) vs. response equation was applied
to evaluate the parallelism between the best-fit hill slopes. The
calibrator was stored at −20◦C in single-use aliquots. The limit
of detection of the assay was expressed as the background
absorbance plus two times the standard deviation (SD). The
precision of the assay was evaluated by calculating the ratio
between the OD and the mean OD of the triplicates of five
donors over a 10-point dilution curve. The dilution linearity was
calculated as the ratio between the interpolated concentration for
each dilution and the mean concentration calculated from the
linear part of the curve. The working range was determined as the
concentrations for which both the ratio OD/mean OD and ratio
concentration/mean concentration had a coefficient of variation
(CV) <20%. Intra-assay variation was calculated as the CV of a
plasma pool in 40 wells of a single microtiter plate. To calculate
the inter-assay variation, serum and plasma pools were run in
triplicates on four separate plates over six different days.
Stability of CL-11 in Serum and Plasma Samples
Serum and plasma samples from three healthy individuals were
stored at 4◦C, RT, or 37◦C for up to 72 h. To study the effect of
repeated freeze-thaw cycles, serum and plasma samples from a
healthy donor were frozen at−80◦C and thawed at RT five times.
The levels of CL-11 were compared to a control sample subjected
to a single freeze-thaw cycle.
Measurement of CL-10/11 Complexes in
Plasma
MaxiSorp microtiter plates were coated overnight at 4◦C with
2µg/ml mAb anti-CL-10 (HM2356, Hycult) in PBS. Serial
dilutions of the calibrator and EDTA plasma 1:40 in sample
buffer were incubated for 2 h. Detection and development were
performed as described in section CL-11 Specific Sandwich
ELISA.
Serum and Plasma Samples
The concentration of CL-11 and CL-10/11 complexes in the
circulation was determined from blood of Danish healthy
volunteers (n = 126). In addition, CL-11 levels were measured
in plasma from patients at admission to an Intensive Care
Unit at Rigshospitalet diagnosed with systemic inflammatory
syndrome (n = 65). The patients have been described elsewhere
(21). Informed consent was obtained from the patients or their
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relatives in accordance with the Helsinki Protocol. The study was
approved by the local ethics committee for Copenhagen County
(record no. KA 96097). Serum and plasma were processed within
1 h of blood collection and stored at−80◦C. Plasma was obtained
by incubating fresh blood with EDTA, citrate, or hirudin—
a naturally occurring anticoagulant that binds to and inhibits
activated thrombin while maintaining complement activity in
blood.
Size Exclusion Chromatography
Serum (100 µl) from a pool of blood donors was applied into a
Superdex 200 HR 10/30 column (GE Healthcare) at a flow rate of
0.5 ml/min at RT with PBS 2mM EDTA. The relative molecular
weight of CL-11 and CL-10/11 complexes was estimated using
a gel filtration marker kit (29–700 kDa, Sigma). CL-11 and
CL-10/CL-11 levels in the elution fractions were measured
by ELISA as described previously. Results were confirmed by
western blotting following Trichloroacetic acid (TCA, Sigma)
precipitation. Briefly, elution fractions (500 µl) were incubated
30min on ice with 10% v/v TCA and centrifuged at 13,000 × g
for 30min at 4◦C. Supernatants were discarded and the pellet was
washed with ice-cold acetone (Sigma) at 13,000 × g for another
30min at 4◦C. Dry precipitates were resuspended in SDS loading
buffer and separated by SDS-PAGE as described above. Anti-
CL-10 (0.05µg/ml, HM2356, Hycult) and pAb rabbit anti-CL-
11 (0.05µg/ml, 15269-1-AP, Proteintech) were used as detection
antibodies with rCL-10 and rCL-11 (in-house) as controls.
Binding of rCL-11 to Ligands
Ligand interaction studies were performed in the fluid and
solid phase. Unless otherwise stated, all reagents were purchased
from Sigma. Fluid phase binding was analyzed by incubating
100 µl of zymosan particles (100 µg, Z4250), mannan-agarose
(M9917), D-mannose-agarose (M6400), and Sepharose CL-2B
(CL2B300) with 2.75 µg of rCL-11 in 500 µl of TBS-Tw-Ca
or TBS-Tw-EDTA for 1.5 h at RT in an end-over-end shaker.
Samples were washed thrice with their respective buffer and
centrifuged at 3000 × g for 30min. Pellets were resuspended
in SDS loading buffer and subjected to SDS-PAGE using
anti-CL-11 Hyb-6 (2µg/ml) and pAb anti-CL-11 (15269-1-AP,
Proteintech) as detection antibodies under non-reducing and
reducing conditions, respectively.
Solid-phase binding was determined on microtiter plates
coated with zymosan (Z4250), mannan (M7504), BSA (A2153),
and D-mannose-BSA (NGP1108, Dextra, UK) in two-fold
dilutions starting at 10µg/ml in PBS overnight at 4◦C. The
plates washed between steps with TBS-Tw, and unless otherwise
stated all incubations took place at RT. rCL-11 (1µg/ml) was
diluted in TBS-Tw-Ca, TBS-Tw-EDTA or TBS-Tw-Mg-EGTA
and incubated for 2 h. Hyb-15 (2µg/ml) in matching buffer was
used as detection antibody for 2 h, followed by 1 h incubation
with Streptavidin-HRP conjugate (RPN1231V) in a 1:2000
dilution. Development was performed as described previously.
To study the effect of soluble inhibitors on the binding to
zymosan and mannan, rCL-11 was incubated with two-fold
dilutions of L-fucose (F2252), N-acetyl-glucosamine (A3286), or
human genomic DNA (isolated in-house) in TBS-Tw-Ca or TBS-
Tw-EDTA for 1 h. Protein/ligandmixes were applied toMaxisorp
plates pre-coated with zymosan or mannan (10µg/ml) and were
allowed to bind for 2 h. Quantification of bound rCL-11 was
carried out as described before.
CL-11 Mediated C4 Deposition on
Zymosan
Microtiter plates were coated as for the solid-phase binding
studies. rCL-11 (2µg/ml) in barbital-Tw or barbital-Tw-EDTA
was applied to the wells and incubated for 2 h at RT, followed by
rMASP-2 produced in CHO DG44 cells (0.5µg/ml, in-house) in
barbital-Tw or barbital-Tw-EDTA for 4 h at 37◦C. Subsequently,
purified C4 (0.5µg/ml, CompTech, USA) in barbital-Tw was
added to the plate for 1 h 37◦C. Polyclonal rabbit anti-C4c
(2µg/ml, Dako) was used as a detection antibody for 1.5 h
at RT, followed by swine anti-rabbit-HRP (0.15µg/ml, P0399,
Dako). The plates were washed between steps with barbital-Tw.
Development and data recoding were carried out as before.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
version 7.02 (GraphPad Software, USA). Measurements of
samples and the calibrator were performed in duplicates unless
otherwise stated. The concentration of CL-11 in serum and
plasma was interpolated by regression analysis using a four-
parameter logistic curve fitting. Effect of storage of CL-11
concentration and differences betweenmeasured CL-11 in serum
and plasma samples was analyzed using two-way ANOVA
with Dunnett’s multiple comparisons tests. Two-tailed person
correlation coefficient was used to determine the correlation
between CL-11 and CL-10/CL-11 levels. Differences between CL-
11 levels in controls and SIRS patients were analyzed with the
Mann-Whitney test. The half maximal inhibitory concentration
(IC50) was calculated using the inhibitor concentration vs.
response equation on a nonlinear curve fitting constraining the
top and bottom parameter to equal 100 and 0, respectively.
The significance of observed differences on C4 deposition
on zymosan was assessed via one-way ANOVA with Tukey’s
corrections for multiple comparisons. Data are represented as
mean± SEM of three independent experiments.
RESULTS
Generation of Anti-CL-11 Monoclonal
Antibodies and Development of A CL-11
Specific Sandwich ELISA
Stable monoclonal hybridoma populations were generated by
several rounds of cloning by limiting dilution. Each cloning
round, culture supernatants were screened by indirect ELISA
with rCL-11. Selected positive clones were characterized further
by immunoprecipitation of native CL-11 from serum followed by
western blotting. As seen in Figure 1, under reducing conditions
both mAbs Hyb-15 and Hyb-17 precipitated a protein with an
apparent molecular mass of ∼34 kDa corresponding to the CL-
11 monomer. Under non-reducing conditions, a characteristic
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FIGURE 1 | Western blot of serum after immunoprecipitation using CL-11
specific mAbs Hyb-17 and Hyb-15 or a mouse IgG1κ isotype control antibody
under reducing and non-reducing conditions. Supernatant from CHO cells
expressing rCL-11 was used as positive control. The blots were developed
with pAb rabbit anti-CL-11.
ladder-like banding pattern is visible with a major protein band
around 180 kDa and several others larger than 250 kDa indicating
that CL-11 assembles into high molecular weight oligomers held
together by interchain disulfide bridges. rCL-11 used as positive
control appeared to form predominantly lower oligomeric forms.
An equivalent banding pattern was also seen with the other tested
mAbs (data not shown). No bands were apparent when using a
mouse IgG1κ control as precipitating antibody.
The best candidates were pairwise screened by sandwich
ELISA against a serum and plasma pool. The optimal
combination and concentration of mAbs was determined using
a two-dimensional of capture and detection antibodies and rated
according to their signal intensity and signal-to-noise ratio. Based
on their properties, Hyb-17 and Hyb-15 were selected as capture
and detection antibody, respectively. No signals were obtained
when an irrelevant mouse antibody was used as capture or
detection antibody (data not shown).
Assay Validation
Supernatant from CHO cells expressing rCL-11 was used as
calibrator. A four-parameter fit model using the equation
log(agonist) vs. response was applied to estimate the
concentration of rCL-11 in the supernatant (R2 > 0.996 for
all curves). Parallelism was observed between the slopes of the
calibrator and two batches of commercial rCL-11 (Figure 2A).
Log-transformed values fitted a linear regression with R2 > 0.98
and the slopes (ranging from 0.56 to 0.58) did not differ
significantly (p > 0.05). Parallelism was also observed between
the slopes of serial dilutions of the calibrator and serum and
plasma pools in the range 0.29–37.5 ng/ml, with slopes between
−0.7 and −0.77 that were not significantly different (p > 0.05)
(Figure 2B). The limit of detection, defined as the mean
background absorbance plus two times the SD, was 0.17 and
0.19 ng/ml in serum and plasma respectively. The precision
of the assay, evaluated using the ratio between individual OD
values and the mean OD values of triplicate measurements for
five different donors (Figure 2C), was found to be acceptable
(CV < 20%) for concentrations above 0.29 ng/ml. To determine
the dilution linearity the ratio between the interpolated
concentrations and the mean concentration of a plasma pool
was calculated for each dilution of a 10-point dilution curve
(Figure 2D). The dilution linearity was satisfactory in the range
0.15–18.75 ng/ml with a deviation under 20% from the mean
concentration. The working range of the assay—defined based
on the parallelism, limit of detection, precision, and dilution
linearity—was 0.29–18.75 ng/ml.
Intra- and inter-assay variation were calculated to estimate
the variation of the assay. The intra-assay CV, calculated by
measuring one sample forty times on the same plate, was 3.96 %
(Table 1). The inter-assay CV was 10.5%, measured in triplicates
on four plates analyzed on six different occasions.
Effect of Storage and Freeze-Thawing
The effect of temperature on the stability of CL-11 in blood
samples was evaluated on matched serum and plasma from three
different donors stored at 4◦C, RT, or 37◦C for up to three
days, whereas the effect of freezing and thawing was studied
on serum and plasma samples from a single donor over five
consecutive cycles. No significant trend on CL-11 levels was
observed when the samples were stored at 4◦C (Figure 3A)
or at RT (Figure 3B), nor after repeated freeze-thawing cycles
(Figure 3D). On the other hand, storage at 37◦C degrees caused
a highly significant drop in CL-11 concentration in citrate and
EDTA plasma (Figure 3C). CL-11 levels in serum and plasma did
not differ significantly.
CL-11 Levels in Plasma
CL-11 concentration in plasma was calculated from EDTA
plasma samples of 126 Danish blood donors (mean 289.4 ng/ml,
range 143.2–459.4 ng/ml) using rCL-11 as calibrator (Figure 4A).
Since it has been reported that a major fraction of CL-11
exists in complex with the homologous CL-10, we measured
the same samples by sandwich ELISA using an anti-CL-10
as capture antibody and anti-CL-11 Hyb-15 as detection. The
estimated mean concentration of CL-10/11 complexes in plasma
was 256.2µg/ml (range 37.89–622.7) and there was a strong
correlation between CL-11 and CL-10/11 levels (r = 0.729,
Figure 4B. A pool of EDTA plasma from 10 healthy individuals
was subjected to size exclusion chromatography followed by
sandwich ELISA in order to define the relationship of CL-11 and
CL-10/11 across their molecular weight distribution (Figure 4C).
CL-11 and CL-10/11 migrated as two major oligomerization
forms of approximately 400 and >600 kDa. ELISA results
were confirmed by western blot using anti-CL-11 (Figure 4D
above) and anti-CL-10 antibodies (Figure 4D below), where
most of the protein is observed in fractions 7–8 and 13–14. Under
reducing conditions, CL-10 migrates as a triple band of∼40 kDa.
CL-11 present in the high molecular weight complexes migrates
as a single band of ∼34 kDa, whereas in the lower oligomers
it appears as a double band—hinting at the occurrence of two
different isoforms.
In light of the tight association between CL-11 and CL-10,
we conclude that the ELISA developed in the current work is
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FIGURE 2 | Sandwich ELISA validation. Parallelism between serial dilutions of rCL-11 produced in CHO cells, used as calibrator, and two different batches of purified
rCL-11 (A) and a serum and plasma pool (B) over a 10-point serial dilution series using a log(agonist) vs. response equation (R2 > 0.99 for all curves). Error bars
indicate the standard deviation of the mean of duplicate measurements. (C) Precision of the assay on plasma from five donors calculated as the range of
concentrations for which the variation of the ratio OD/mean OD of the triplicates is <20% (i.e., > 0.293 ng/ml). (D) Dilution linearity on plasma from five donors
calculated as the range of concentrations for which the variation of the interpolated concentration/mean concentration of the triplicates is <20% (i.e.,
0.146–18.75 ng/ml).
TABLE 1 | Intra- and inter-assay variation of ELISA.
Sample n CL-11(ng/ml) SD CV(%)
Mean Range
INTRA-ASSAY VARIATION
Plasma 40 282.6 250.2–299.1 11.2 3.96
INTER-ASSAY VARIATION
Plasma 6 286.7 257–335.2 30.1 10.5
Serum 6 247.1 187.8–331.7 49.47 20.02
The intra-assay variation was calculated by measuring a plasma pool sample on the same
microtiter plate. The inter-assay variation was determined by comparing the mean of
triplicates of a serum and plasma pool on four microtiter plates on six different days.
accurate and relevant to describe the natural situation of CL-11
in the circulation.
CL-11 Levels in Patients With Systemic
Inflammatory Response Syndrome (SIRS)
Since CL-11 is expected to participate in the response
against invading pathogens by activating the lectin pathway
of complement, we measured the levels of CL-11 in 65
randomly selected plasma samples from patients admitted to
the intensive care unit with SIRS [reported elsewhere(21)]
(Figure 5A). Compared to healthy controls (n = 69), CL-11 was
significantly decreased in patients with SIRS and spanned a wider
range of concentrations (mean 276.4 ng/ml, range 136.2–511.7
vs. 240 ng/ml, range 73.76–876.4 ng/ml for controls and SIRS
patients, respectively). As observed in healthy individuals, the
concentration of CL-11 in SIRS plasma was strongly correlated
with that of CL-10/11 complexes (r = 0.915, Figure 5B).
Ligand Characterization
Using our validated antibodies, we studied the ligand binding
characteristics of CL-11 to identify a suitable ligand for in vitro
complement activation assays. Binding was performed in the
presence of calcium or EDTA (as cationic chelator) in the fluid
phase using zymosan particles, mannan-agarose, D-mannose-
agarose, and Sepharose as negative control. CL-11 displayed a
characteristic C-type lectin activity and bound to D-mannose
and mannan in the presence of calcium (1, 6) (Figures 6A,B).
Remarkably, CL-11 was also able to bind to zymosan in a
calcium-independent manner, suggesting an alternative ligand
recognition mechanism. We confirmed the results by coating
two-fold dilutions of mannan, zymosan, D-mannose-BSA, and
BSA as negative control (Figures 6C–F). Binding of rCL-11
(1µg/ml) was performed in the presence of calcium, EDTA,
and magnesium-EGTA (a commonly used buffer for alternative
pathway activation). As seen in the fluid-phase assay, calciumwas
required for binding to mannan and D-mannose (Figures 6C,E)
but not to zymosan (Figure 6D). No binding to BSA was
observed regardless of the buffer (Figure 6F).
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FIGURE 3 | Sample stability. Effect of temperature on CL-11 concentration in serum and plasma from three donors after storage at 4◦C (A), RT (B), or 37◦C (C) for
three days. (D) Effect of freeze-thawing cycles on CL-11 measurements serum and plasma from the same donor. *p < 0.05, **p < 0.01; ***p < 0.001; ¤, p = 0.0001.
In order to determine whether the observed binding profiles
are a result of the involvement of different binding sites for
mannan and zymosan, we compared the effect of L-fucose (a
strong ligand), N-Acetyl glucosamine (GlcNAc, a weak ligand),
and genomic DNA (a calcium-independent ligand) on the
binding to mannan and zymosan (Figure 7). Briefly, CL-11 was
co-incubated with serial dilutions of L-fucose or GlcNAc starting
in a 125mM, or human genomic DNA starting at 30µg/ml prior
to addition to coated plates. L-fucose was an effective inhibitor of
the binding to mannan in the presence of calcium with an IC50
of 36.48mM, whereas N-acetyl-glucosamine had just a minor
effect (IC50 > 125mM) (Figure 7A). On zymosan, L-fucose was
only a moderate inhibitor in the presence of calcium, forming
an apparent plateau around 50% inhibition, while GlcNAc had
no effect (Figure 7B). The limited effect of L-fucose suggests
the presence of two separate binding sites for zymosan and
carbohydrates.
CL-11 has been reported to bind to DNA in a calcium-
independent fashion via an alternative binding-site. Co-
incubation with DNA in the presence of calcium increased the
binding to mannan, suggesting a cooperative effect between both
molecules (see Discussion) (Figure 7C). DNA did not affect
zymosan binding under calcium conditions, whereas in EDTA
it showed a pronounced inhibition with an IC50 of 2.3µg/ml
(Figure 7D). These results indicate the presence of a shared
binding site for nucleic acids and zymosan. Bearing all of the
above in mind, we have identified a novel interaction with
zymosan independent of divalent cations that we hypothesize
may be relevant in environments where the binding to calcium
is impaired, such as the gastrointestinal tract.
CL-11-Mediated C4 Deposition on
Zymosan
To investigate if CL-11 bound to zymosan could trigger the
lectin complement pathway, we developed an in vitro assay using
rMASP-2 and purified C4 (Figure 8). CL-11/MASP-2 complexes
on zymosan caused a significant C4b deposition under calcium
conditions in a level comparable to mannan. In the presence of
EDTA, C4 activation was only seen on the zymosan ligand. No
C4b deposition was observed on BSA, nor in the absence of CL-11
and MASP-2.
DISCUSSION
We have generated mAbs against human CL-11 and established
a quantitative sandwich ELISA. The antibody-producing
hybridomas underwent successive selection rounds using first
rCL-11, and later serum and plasma by ELISA and western
immunoblotting. While all clones readily bound rCL-11, just
a few reacted strongly with native CL-11. This is probably
due to the existence of complexes in the circulation that
hide epitopes otherwise exposed in the homomeric rCL-11
used as immunogen. In fact, immunoprecipitation of serum
demonstrates that native CL-11 has a different oligomeric
distribution than our recombinant protein (Figure 1). The
best candidates were pairwise compared to develop a sandwich
Frontiers in Immunology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 2238
Bayarri-Olmos et al. Characterization of Human CL-11
FIGURE 4 | Concentration and molecular weight distribution of CL-11 and CL-10/11 complexes in plasma. (A) CL-11 and CL-10/11 concentration in plasma of 126
Danish blood donors using the validated assay described here and a semi quantitative CL-10/CL-11 sandwich ELISA. Horizontal lines represent mean. (B)
Spearman’s rank correlation between measured CL-11 and CL-10/11 levels. (C) Detection of CL-11 and CL-10/11 complexes in the elution fractions of size exclusion
chromatography of plasma by sandwich ELISA. Relative levels of CL-11 and CL-10/11 complexes in the elution fractions are reported as arbitrary units (AU). Vertical
dotted lines indicate the molecular masses of thyroglobulin (669 kDa), apoferritin (443 kDa), β-amylase (200 kDa), alcohol dehydrogenase (150 kDa), BSA (66 kDA),
carbonic anhydrase (29 kDa). Western blot of elution fractions from size exclusion chromatography using Hyb-6 anti-CL-11 (D above) or anti-CL-10 (D below).
rCL-11 and rCL-10 produced in CHO cells were used as positive controls.
FIGURE 5 | CL-11 levels in plasma from patients with SIRS and controls. (A) CL-11 concentration was measured in 65 SIRS plasma samples and 69 controls using
the quantitative ELISA described here. Horizontal lines represent mean. (B) Spearman’s rank correlation between CL-11 and CL-10/11 concentration in SIRS plasma
samples.
ELISA. Two antibodies were selected as capture and detection
antibody in the basis of their signal-to-noise ratio. The assay
was validated in terms of linearity, variability, and precision,
demonstrating a satisfactory variability, and parallelism between
calibrator and serum and plasma across a working range of 0.29–
18.75 ng/ml (Figure 2). We observed no significant differences
between CL-11 concentration in serum and four different widely
used plasma preparations (Figure 3). Similarly, common storage
conditions and freeze-thawing procedures did not affect the
measurements of CL-11, highlighting the suitability of this assay
for routine measurements in the clinic. Of interest, some of the
mAbs cross-reacted with CL-11 from other species, granting the
possibility of forthcoming studies into CL-11 in animal models
of disease.
When optimizing the sandwich ELISA we noticed that EDTA
was required to detect native CL-11 in serum and plasma (but not
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FIGURE 6 | Characterization of CL-11 ligand binding. Western blot of rCL-11 co-precipitated with zymosan particles, mannan-agarose, D-mannose-agarose, or
Sepharose in the presence of Ca2+ or EDTA under non-reducing (A) and reducing conditions (B). Binding of rCL-11 (1µg/ml) to serial dilutions of coated
D-mannose-BSA (C), mannan (D), zymosan (E), and BSA (F) in the presence of Ca2+, EDTA, and Mg2+-EGTA. Data is reported as mean ± SEM of three
independent experiments.
rCL-11) (Supplementary Figures 1A–C). Moreover, Western
blot results following immunoprecipitation of serum CL-11
in a calcium-containing buffer vs. EDTA buffer resulted in a
different banding pattern (Supplementary Figure 1D). Calcium
stabilizes the tertiary structure of the CRD of CL-11 (10), and
is required for the association of the MASPs with the collagen
stalks of the PRMs (22, 23). To determine whether the EDTA-
dependent detection of native CL-11 was due to a change in
its three-dimensional structure or masking of the epitope by
bound MASPs, we incubated rCL-11 in the presence of calcium,
EDTA, and MASP-3. Calcium and MASP-3 had no effect on the
detection of rCL-11. It has been frequently observed that serum
can inhibit the binding of spiked collectins and ficolins to their
ligands (14). This inhibition is greatly reduced when using EDTA
in the dilution buffer. At the same time others have reported
the use of a calcium-dependent antibody for the purification
of native CL-10/11 complexes (24). Our hypothesis is that CL-
11 (or CL-10) exists in a calcium-dependent complex with a
hitherto unknown protein that both interferes with detection of
native CL-10/11 complexes at low serum dilutions and inhibits
the binding of spiked CL-11.
Since it appears that CL-11 is found in the circulation
associated with the homologous CL-10 (14), we used our
assay and a semiquantitative ELISA to compare the levels of
CL-11 and CL-10/11 complexes in plasma from Danish blood
donors (Figure 4). The mean plasma concentration of CL-11
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FIGURE 7 | Inhibition of binding of rCL-11 to coated mannan (A,C) or zymosan (B,D). Serial dilutions of L-fucose (L-fuc), N-acetyl-glucosamine (GlcNAc), or genomic
DNA were incubated with rCL-11 (1µg/ml) in the presence of Ca2+ or EDTA. Data is reported as percent binding compared to the well without inhibitor. Bound
rCL-11 was measured with biotinylated mAb anti-CL-11 Hyb-15. Connecting lines represent nonlinear regression fits using the equation inhibitor concentration vs.
response with variable slope. Data is reported as mean ± SEM of three independent experiments.
FIGURE 8 | C4 deposition on zymosan. CL-11 (2µg/ml) was allowed to bind to zymosan or mannan-coated plates (10 µ/ml) for 2 h in the presence of calcium or
EDTA, followed by incubation with rMASP-2 (0.5µg/ml) and purified C4 (0.5µg/ml) for 4 h and 1 h respectively at 37◦C. C4b deposition was measured using a pAb
anti-C4c. Data is reported as mean ± SEM of three independent experiments. Numbers between parentheses are columns compared by ANOVA. **p < 0.01;
****p < 0.0001.
was 289.4 ng/ml, range 143.2–459.4 ng/ml, in agreement with two
previously published Danish and Japanese cohorts (284 ng/ml
and 340 ng/ml, respectively) (7, 25), and equivalent to the
estimated concentration of CL-10/11 (256.2 ng/ml, range 37.89–
622.7 ng/ml). However, we want to remark that lacking a carefully
validated ELISA for CL-10/11, the later concentration is merely
an educated guess. There was a strong correlation between CL-11
and CL-10/11 levels in plasma (r = 0.729) apparent across a
wide range of molecular masses after subjecting plasma to size
exclusion chromatography and measuring the levels of CL-11
and CL-10/11 in the elution fractions by ELISA and western
blot. This tight association previously reported for CL-11 and
CL-10 (26–28), conforms with quantitative mass spectrometry
estimates suggesting that the CL-10/11 subunit is composed
of one CL-11 and two CL-10 polypeptide chains (14). Plasma
CL-11 and CL-10/11 eluted as two distinct peaks at 300–400
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kDa and >600 kDa that may correspond with tetramers of
trimeric subunits and higher forms, respectively. Although direct
area-under-the-curve comparisons suggest that most of CL-10
and CL-11 exist as high molecular weight complexes in the
circulation, the lack of resolution beyond 700 kDa makes it
impossible to differentiate hexamers of trimers from higher
oligomeric forms, that could otherwise elute in distinct peaks
with a similar area-under-the-curve as the ∼400 kDa peak.
Western blot of the elution fractions under-reducing conditions
revealed multiple monomer bands for CL-10 and CL-11 in
agreement with the observations of Henriksen et al. that CL-10
is found in the circulation as three glycosylated states and CL-
11 as two differentially-spliced isoforms (14). Detection of CL-11
demonstrated the presence of a second band in the lowmolecular
weight complexes, possibly corresponding to the shorter isoform
D. Of the five isoforms predicted to be secreted by in silico
analyses (29), only isoform A and D have been detected in
blood (1, 14, 25). Isoform D has a shorter collagen-like domain
(48 amino acids as opposed to 72 in isoform A) and lacks
the putative MASP-binding motif HGKIGP (Figure 9). Though
shorter, isoform D maintains intact the Gly-X-Y repeats of the
collagen-like domain required for the formation of interchain
FIGURE 9 | Exon and domain organization of CL-11 isoforms. The five isoforms predicted to be secreted are aligned from the N-terminus (A) with the missing amino
acids represented by tildes (∼), or from the cysteine pair in the neck domain (B). Exons 5 to 7, numbered according to isoform a, are shown once for they are
conserved between isoforms. Cysteines are highlighted in yellow, glycines in Gly-X-Y collagen repeats in blue, amino acids involved in carbohydrate binding in red.
Grey box, putative MASP-binding motif. Isoform a, NM_024027.4; isoform c, NM_001255982.1; isoform d, NM_001255983; isoform e, NM_001255984.1; isoform f,
NM_001255985.1.
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hydrogen bonds and stabilization of the collagen triple helix
(30, 31). Because the C-terminus of isoforms A and D are
identical, we hypothesize that the neck domain could direct
the assembly of a trimer with a ragged N-terminal region with
cysteines incapable of stabilizing high order oligomeric structures
(32). Detection of CL-10 in the elution fractions revealed that
non- or singly-glycosylated CL-10 was more abundant in the
∼600 kDa oligomers, while the doubly-glycosylated form was
more abundant in the∼400 kDa complexes. It has been suggested
that CL-11 stabilizes and facilitates secretion of CL-10 (14), in
part due to the difficulties of expressing the CL-10 recombinantly
(33, 34). In the current work we describe the production of
rCL-10 using stable transfected CHO cells. The protein was
secreted into the supernatant and appeared to form oligomers of
trimers (data not shown). Further studies in the characterization
of homomeric CL-10 and the influence of alternative spliced
variants and glycosylation states in the oligomerization of CL-
10/11 are guaranteed, as are studies on the effect (if any)
of the isoform D lacking the MASP binding motif in the
weak interaction of low molecular weight CL-10/11 with the
MASPs.
Based on the putative role of CL-11 in the modulation of
the immune response against pathogens (2, 9), we performed a
pilot study on randomly-selected plasma samples from patients
diagnosed with SIRS (Figure 5). Notably, the mean CL-11
plasma concentration was significantly decreased in SIRS patients
upon admission compared to healthy controls (p < 0.0001).
Nonetheless, we choose to remain cautious and refrain from
any biological interpretation until a thorough analysis of new
ongoing projects can be performed. The levels of homomeric
and heteromeric CL-11 were strongly associated in SIRS patients
(r = 0.915), as seen for healthy controls, reinforcing the current
opinion that CL-10 and CL-11 are co-regulated and exist as a
hybrid molecule.
CL-11 has been shown to bind to several microorganisms
(6), with a preference for complex sugars as opposed to other
collectins (10). Using the developed mAbs we confirmed that
our in-house recombinant protein displays the characteristics
of native CL-11 and binds to mannan and D-mannose in a
calcium-dependent manner (Figure 6). As expected, L-fucose—
but not GlcNAc—was an effective inhibitor of the binding to
mannan (IC50 = 36.48mM). Interestingly, rCL-11 also bound
to zymosan in a calcium-independent manner that could be
only partially inhibited by L-fucose in the presence of calcium.
Zymosan is a major constituent of the cell wall of the yeast
Saccharomyces cerevisiae. It is composed mainly of cross-linked
β-glucan and α-mannan, and has been widely used to elicit
immune and inflammatory responses (35–38). Several calcium-
independent ligands, such as nucleic acids, have been reported
for CL-11 reflecting complex interactions beyond its lectin
activity (2, 10, 19). Thus, we incubated rCL-11 with DNA and
measured the amount of bound CL-11 to coated mannan and
zymosan (Figure 7). On mannan DNA appeared to increase the
binding to the coated ligand. The same phenomenon has been
reported by Henriksen et al., where the authors concluded that
DNA may increase the avidity or align the CRDs in a more
favorable conformation (19). On zymosan, DNA had a minor
effect in calcium, while in EDTA buffer it was a moderately
effective inhibitor (IC50 = 2.3µg/ml). We propose that CL-
11 recognizes zymosan via two distinct mechanisms: a classical
calcium-dependent lectin activity, and an alternative calcium-
independent interaction shared with nucleic acids. Other C-type
lectins, such as dectin-1 and Reg family proteins III and IV,
are also capable of recognizing fungal and bacterial ligands in
a metal ion-independent fashion (39–41). Interestingly, it has
been proposed that the Reg family proteins evolved to bind
sugars without calcium to carry their antimicrobial function in
the gastrointestinal tract, where the low pHmay impair the ability
of classical C-type lectins to bind to carbohydrates. Similar low
pH, low calcium conditions result from infection-induced local
inflammation (42). Immunohistochemical analyses have revealed
that CL-11 is expressed (among others) in the stomach and the
intestines (11). At this stage we can only conjecture whether the
calcium-independent zymosan interaction may be of biological
relevance in acidic environments with low calcium availability.
Finally, we measured the ability of rCL-11 to trigger lectin
pathway activation on zymosan (Figure 8). It has been reported
that serum inhibits the binding of purified and recombinant
collectins and ficolins to their ligands (14). At the same time,
the relatively low concentration of CL-11 in circulation requires
using serum dilutions that would trigger complement activation
via the alternative pathway. To circumvent these limitations, we
employed a step-wise activation assay using recombinant and
purified proteins in a buffer that allows the cleavage of C4 by
MASP-2—the first step of the activation of the lectin pathway.
Binding of rCL-11 followed by incubation with rMASP-2 and
purified C4 resulted in the deposition of C4b on coated zymosan,
comparable to that on mannan. Calcium was not necessary for
the binding of rCL-11 to zymosan, but for the complex formation
with rMASP-2.We consider that not requiring calcium is an asset
when designing a specific assay to discriminate the contribution
of CL-11 from the other PRMs of the lectin pathway.
In conclusion, we have developed monoclonal antibodies and
a robust and sensitive sandwich ELISA for the quantification of
CL-11 in the circulation and used them to study native CL-11
in plasma and the binding characteristics of rCL-11 to different
ligands.
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Supplementary Figure 1 | Effect of calcium in the detection of native CL-11.
The concentration of CL-11 was measured in three different donors in a
three-fold dilution of serum (A) and plasma (B) or supernatant from CHO cells
(C) with and without EDTA the sample buffer. (D) Western blot of
immunoprecipitation (IP) of CL-11 from serum in a calcium or EDTA-containing
buffer under non-reducing conditions. Lanes 1 and 2, purified rCL-11 and
supernatant from CHO cells expressing rCL-11. Lane 3, serum before IP.
Lanes 4 to 9, serum after IP using CL-11 specific mAbs Hyb-15 and Hyb-17
or a mouse IgG1κ isotype control antibody. The blots were developed with
pAb rabbit anti-CL-11. ELISA, IP and Western blotting were performed
according to sections CL-11 Specific Sandwich ELISA, Immunoprecipitation,
SDS-page and western blot, respectively.
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